Acrivon Therapeutics (ACRV)
Market Price (8/31/2026): $2.1 | Market Cap: $87.9 MilSector: Health Care | Industry: Biotechnology
Acrivon Therapeutics (ACRV)
Market Price (8/31/2026): $2.1Market Cap: $87.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -102% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -156% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -78 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -91% Key risksACRV key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -102% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -156% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -78 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -91% |
| Key risksACRV key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/26/2026
Acrivon Therapeutics (ACRV) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Positive Clinical Trial Progress for ACR-2316.
Acrivon Therapeutics announced in August 2026 the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. This progression was supported by a favorable safety profile and durable single-agent clinical activity, including partial responses in lung and endometrial cancer patients, with some heavily pretreated lung cancer subjects remaining on treatment for over one year.
2. Strong Fiscal Q2 2026 Earnings Beat and Extended Cash Runway.
On August 12, 2026, Acrivon Therapeutics reported its fiscal Q2 2026 financial results, with an earnings per share (EPS) of -$0.43, exceeding analysts' consensus estimates of -$0.50 by $0.07. The company also highlighted its cash, cash equivalents, and marketable securities totaling $90.0 million as of June 30, 2026 (the end of fiscal Q2 2026), which is projected to fund operations into fiscal Q4 2027, thereby extending its financial runway.
Show more
Acrivon Therapeutics (ACRV) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Positive Clinical Trial Progress for ACR-2316.
Acrivon Therapeutics announced in August 2026 the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. This progression was supported by a favorable safety profile and durable single-agent clinical activity, including partial responses in lung and endometrial cancer patients, with some heavily pretreated lung cancer subjects remaining on treatment for over one year.
2. Strong Fiscal Q2 2026 Earnings Beat and Extended Cash Runway.
On August 12, 2026, Acrivon Therapeutics reported its fiscal Q2 2026 financial results, with an earnings per share (EPS) of -$0.43, exceeding analysts' consensus estimates of -$0.50 by $0.07. The company also highlighted its cash, cash equivalents, and marketable securities totaling $90.0 million as of June 30, 2026 (the end of fiscal Q2 2026), which is projected to fund operations into fiscal Q4 2027, thereby extending its financial runway.
Show more
Updated on 8/26/2026
Acrivon Therapeutics (ACRV) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Positive Clinical Trial Progress for ACR-2316.
Acrivon Therapeutics announced in August 2026 the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. This progression was supported by a favorable safety profile and durable single-agent clinical activity, including partial responses in lung and endometrial cancer patients, with some heavily pretreated lung cancer subjects remaining on treatment for over one year.
2. Strong Fiscal Q2 2026 Earnings Beat and Extended Cash Runway.
On August 12, 2026, Acrivon Therapeutics reported its fiscal Q2 2026 financial results, with an earnings per share (EPS) of -$0.43, exceeding analysts' consensus estimates of -$0.50 by $0.07. The company also highlighted its cash, cash equivalents, and marketable securities totaling $90.0 million as of June 30, 2026 (the end of fiscal Q2 2026), which is projected to fund operations into fiscal Q4 2027, thereby extending its financial runway.
3. Encouraging Clinical Data for ACR-368 and Anticipated Near-Term Catalysts.
The fiscal Q1 2026 financial report on May 13, 2026, revealed compelling interim Phase 2b data for ACR-368, demonstrating a 52% confirmed overall response rate in serous endometrial cancer subjects. The company also reiterated its plans for a prespecified interim analysis of the registrational-intent ACR-368 Phase 2b study in the second half of 2026, acting as a significant near-term clinical catalyst.
Show less
Acrivon Therapeutics (ACRV) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Positive Clinical Trial Progress for ACR-2316.
Acrivon Therapeutics announced in August 2026 the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. This progression was supported by a favorable safety profile and durable single-agent clinical activity, including partial responses in lung and endometrial cancer patients, with some heavily pretreated lung cancer subjects remaining on treatment for over one year.
2. Strong Fiscal Q2 2026 Earnings Beat and Extended Cash Runway.
On August 12, 2026, Acrivon Therapeutics reported its fiscal Q2 2026 financial results, with an earnings per share (EPS) of -$0.43, exceeding analysts' consensus estimates of -$0.50 by $0.07. The company also highlighted its cash, cash equivalents, and marketable securities totaling $90.0 million as of June 30, 2026 (the end of fiscal Q2 2026), which is projected to fund operations into fiscal Q4 2027, thereby extending its financial runway.
3. Encouraging Clinical Data for ACR-368 and Anticipated Near-Term Catalysts.
The fiscal Q1 2026 financial report on May 13, 2026, revealed compelling interim Phase 2b data for ACR-368, demonstrating a 52% confirmed overall response rate in serous endometrial cancer subjects. The company also reiterated its plans for a prespecified interim analysis of the registrational-intent ACR-368 Phase 2b study in the second half of 2026, acting as a significant near-term clinical catalyst.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 11.4% change in ACRV stock from 4/30/2026 to 8/30/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8302026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.85 | 2.06 | 11.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 39 | 42 | -7.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 8/30/2026| Return | Correlation | |
|---|---|---|
| ACRV | 11.4% | |
| Market (SPY) | 7.1% | 31.5% |
| Sector (XLV) | 17.2% | 9.5% |
Fundamental Drivers
The 15.1% change in ACRV stock from 1/31/2026 to 8/30/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 8302026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.79 | 2.06 | 15.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 39 | 42 | -7.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/30/2026| Return | Correlation | |
|---|---|---|
| ACRV | 15.1% | |
| Market (SPY) | 11.5% | 37.1% |
| Sector (XLV) | 11.1% | 12.0% |
Fundamental Drivers
The 60.9% change in ACRV stock from 7/31/2025 to 8/30/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 8302026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.28 | 2.06 | 60.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 38 | 42 | -8.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/30/2026| Return | Correlation | |
|---|---|---|
| ACRV | 60.9% | |
| Market (SPY) | 22.7% | 27.0% |
| Sector (XLV) | 32.9% | 17.1% |
Fundamental Drivers
The -83.4% change in ACRV stock from 7/31/2023 to 8/30/2026 was primarily driven by a -69.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8302026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.44 | 2.06 | -83.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 13 | 42 | -69.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2023 to 8/30/2026| Return | Correlation | |
|---|---|---|
| ACRV | -83.4% | |
| Market (SPY) | 74.0% | 25.1% |
| Sector (XLV) | 33.6% | 20.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ACRV Return | - | -31% | -57% | 22% | -60% | -11% | -87% |
| Peers Return | 6% | -56% | 27% | -44% | 19% | 92% | -25% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| ACRV Win Rate | - | 0% | 33% | 50% | 67% | 38% | |
| Peers Win Rate | 50% | 33% | 50% | 37% | 43% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ACRV Max Drawdown | - | - | -84% | -49% | -85% | -57% | |
| Peers Max Drawdown | -48% | -78% | -60% | -68% | -65% | -38% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ZNTL, APRE, IDYA, TNGX, ORIC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/28/2026 (YTD)
About Acrivon Therapeutics (ACRV)
Acrivon Therapeutics (ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company distinguishes itself by moving beyond traditional genomics-based patient selection methods, which often target a small percentage of cancer patients. Instead, Acrivon employs its proprietary proteomics-based platform, Acrivon Predictive Precision Proteomics (AP3), to create drug-specific OncoSignature companion diagnostics. This innovative platform directly measures critical tumor-driving proteins to identify patients whose tumors are predicted to be most sensitive to a specific medicine, thereby expanding the potential treatable population across a broader range of cancers.
The company's lead product candidate is ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2. ACR-368 is currently advancing in a potentially registrational Phase 2 trial under an FDA master protocol, initially focusing on patients with platinum-resistant ovarian, endometrial, or bladder cancer. Patients in this trial are stratified for treatment based on their OncoSignature-predicted sensitivity to ACR-368. Acrivon also plans to study ACR-368 in additional indications such as HPV+ squamous cell carcinomas, building on demonstrated clinical activity and OncoSignature-based predictions of sensitivity.
In addition to ACR-368, Acrivon is developing a preclinical pipeline of internally discovered programs targeting key nodes in DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. By leveraging its AP3 platform, Acrivon aims to significantly accelerate drug development, increase the probability of successful treatment outcomes, and ultimately address a much larger percentage of solid tumors for which genetics-based approaches have been insufficient to identify patient responders.
AI Analysis | Feedback
Here are 1-3 brief analogies for Acrivon Therapeutics:
- Acrivon Therapeutics is like 23andMe for cancer treatment, but instead of using DNA to understand inherited risks, they use protein analysis to precisely match patients with the right drugs for their tumor.
- Acrivon is like Waze for cancer drug development, using real-time molecular insights (proteins) to find the most efficient path for a drug to reach the right patients, rather than relying on older, static maps (genetics).
AI Analysis | Feedback
- ACR-368 (Prexasertib): A clinical-stage small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for various solid tumors.
- Acrivon Predictive Precision Proteomics (AP3) Platform: A proprietary proteomics-based platform used to identify patient responders for oncology drug candidates and create drug-specific OncoSignature companion diagnostics.
AI Analysis | Feedback
As a clinical-stage biopharmaceutical company, Acrivon Therapeutics (ACRV) is currently focused on the development of precision oncology medicines and companion diagnostics, advancing its lead candidate, ACR-368, through Phase 2 clinical trials. At this stage of development, the company does not have commercial products on the market.
Therefore, Acrivon Therapeutics does not currently have major customers that purchase its products or services.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
The key risks to Acrivon Therapeutics' business are:
- Clinical Trial Success and Regulatory Approval of Lead Drug Candidate (ACR-368): Acrivon is a clinical-stage biopharmaceutical company, and the success of its lead candidate, ACR-368, in its ongoing "potentially registrational Phase 2 trial" is paramount. There is inherent risk in drug development, and failure to achieve favorable results in clinical trials or to obtain regulatory approval from bodies like the FDA would significantly impact the company's ability to commercialize its primary asset.
- Regulatory Approval and Efficacy of the AP3 Platform and OncoSignature Companion Diagnostics: Acrivon's core strategy relies on its proprietary proteomics-based patient responder identification platform (AP3) and its drug-specific OncoSignature companion diagnostics. The company explicitly states that its "ACR-368 OncoSignature test... has not yet obtained regulatory approval." The successful development, validation, and regulatory approval of this companion diagnostic are critical to its precision medicine approach and its ability to identify patient responders, which it believes will increase overall response rates and accelerate clinical development. Failure to secure regulatory approval for this platform or if it does not perform as anticipated in identifying sensitive patients, would undermine its entire business model and pipeline.
AI Analysis | Feedback
The primary clear emerging threat for Acrivon Therapeutics is the regulatory approval and prospective clinical validation of its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), and its associated OncoSignature companion diagnostic. The company explicitly states that the "ACR-368 OncoSignature test, which has not yet obtained regulatory approval." The success of their lead candidate, ACR-368, in its potentially registrational Phase 2 trial is contingent upon this OncoSignature test successfully identifying patient responders and receiving regulatory approval. A failure to secure regulatory approval for the diagnostic, or if the AP3 platform and OncoSignature test fail to demonstrate robust prospective predictive power and patient enrichment in the ongoing registrational-intent clinical trials, would undermine Acrivon Therapeutics' core precision oncology strategy and its ability to bring its drug candidates to market as intended.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Acrivon Therapeutics (ACRV) over the next 2-3 years:
- Advancement and potential regulatory approval of ACR-368 (prexasertib) for initial indications: Acrivon is currently advancing its lead candidate, ACR-368, in a potentially registrational Phase 2 trial for patients with platinum-resistant ovarian, endometrial, or bladder cancer. Successful completion of this trial and subsequent regulatory approval would be a primary driver of revenue growth as the company could begin commercializing the drug in these high-unmet-need indications.
- Expansion of ACR-368 into additional tumor types: Beyond its initial registrational trial, Acrivon plans to study ACR-368 in additional indications, such as human papilloma virus positive (HPV+) squamous cell carcinomas, including head and neck (SCCHN), anal, and cervical cancer. Successful clinical development and eventual approval in these expanded markets would significantly broaden the patient population and potential revenue streams for ACR-368.
- Commercialization and adoption of the proprietary OncoSignature companion diagnostic: Integral to Acrivon's strategy is its proprietary proteomics-based patient responder identification platform, AP3, which enables the creation of drug-specific OncoSignature companion diagnostics. The successful development, regulatory approval, and widespread adoption of the ACR-368 OncoSignature test are crucial for identifying patient responders and maximizing the efficacy and market potential of ACR-368, indirectly driving drug revenue and potentially generating revenue from the diagnostic itself.
- Strategic partnerships and collaborations: As Acrivon progresses its lead candidate ACR-368 and its innovative AP3 platform, the company may pursue strategic partnerships or collaborations. These could involve licensing agreements for specific regions, co-development deals, or partnerships to apply the AP3 platform to other drug candidates, generating revenue through upfront payments, milestone achievements, and royalties.
AI Analysis | Feedback
Share Issuance
- Acrivon Therapeutics priced its initial public offering on November 14, 2022, offering 7,550,000 shares of common stock at a price of $12.50 per share.
- Concurrently with the IPO in November 2022, the company sold an additional 400,000 shares of common stock to an existing stockholder, Chione Limited, through a private placement. The gross proceeds from the IPO and this concurrent private placement were approximately $99.4 million.
- In April 2024, Acrivon completed a private investment in public equity (PIPE) financing, issuing 8,235,000 shares of common stock at $8.50 per share and pre-funded warrants for up to 7,060,000 shares at $8.499 per warrant, raising approximately $130 million in gross proceeds.
Inbound Investments
- Prior to its IPO in November 2022, Acrivon Therapeutics secured $100 million in an oversubscribed Series B financing round in November 2021.
- The company completed a private investment in public equity (PIPE) financing in April 2024, with new and existing accredited investors providing approximately $130 million in gross proceeds.
Capital Expenditures
- Acrivon Therapeutics invested $899K in capital expenditures in Q3 2025, primarily funding long-term assets and infrastructure.
- Capital expenditures for the 12 months prior to Q3 2025 amounted to $2.28 million.
- The company anticipates that its cash, cash equivalents, and investments are sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
Peer Outperformance in Biotechnology
nullShare of Biotechnology constituents that ACRV has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
67%
of 459 industry peers · 53.7% return
3Y
24%
of 405 industry peers · -82.4% return
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is ACRV's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 11.3% | 87.6% | 129.3% | CAH 398% · MCK 348% · COR 178% |
| Managed Health Care | 8 | 29.5% | -0.6% | 2.9% | OSCR 95% · HQY 50% · ELV 13% |
| Health Care Services | 20 | 19.7% | 40.8% | 1.0% | HIMS 266% · RDNT 138% · DGX 75% |
| Health Care Facilities | 24 | 6.2% | -4.5% | -18.3% | THC 254% · NHC 246% · ENSG 114% |
| Health Care Equipment | 51 | -3.6% | -6.4% | -20.1% | POCI 10900% · UFPT 329% · GKOS 202% |
| Health Care Supplies | 12 | 32.6% | -15.8% | -36.7% | LNTH 282% · HAE 66% · MMSI 26% |
| Pharmaceuticals | 63 | -3.1% | 8.0% | -38.3% | LQDA 2435% · INDV 1218% · ETON 1034% |
| Life Sciences Tools & Services | 108 | 1.5% | -32.7% | -70.0% | SNWV 1808% · MEDP 229% · AXGN 202% |
| Health Care Technology | 21 | -25.9% | -57.7% | -75.1% | SPOK 79% · HSTM -2% · VEEV -17% |
| Biotechnology ← | 365 | 10.0% | -25.2% | -79.0% | BRTX 99450% · DNTH 1554% · CELZ 1529% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Acrivon Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.52 |
| Mkt Cap | 0.9 |
| Rev LTM | 0 |
| Op Inc LTM | -145 |
| FCF LTM | -113 |
| FCF 3Y Avg | -125 |
| CFO LTM | -112 |
| CFO 3Y Avg | -124 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 121.5% |
| Rev Chg 3Y Avg | 539.1% |
| Rev Chg Q | -100.0% |
| QoQ Delta Rev Chg LTM | -0.8% |
| Op Inc Chg LTM | 12.0% |
| Op Inc Chg 3Y Avg | -13.2% |
| Op Mgn LTM | -173.0% |
| Op Mgn 3Y Avg | -1,399.0% |
| QoQ Delta Op Mgn LTM | -29.2% |
| CFO/Rev LTM | -157.6% |
| CFO/Rev 3Y Avg | -1,082.6% |
| FCF/Rev LTM | -158.4% |
| FCF/Rev 3Y Avg | -1,097.5% |
Price Behavior
Price Behavior
| Market Price | $2.06 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/15/2022 | |
| Distance from 52W High | -31.6% | |
| 50 Days | 200 Days | |
| DMA Price | $1.80 | $1.87 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 14.6% | 10.4% |
| 3M | 1YR | |
| Volatility | 73.3% | 95.8% |
| Downside Capture | 52.96 | 195.86 |
| Upside Capture | 168.53 | 204.93 |
| Correlation (SPY) | 33.5% | 26.5% |
ACRV Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.75 | 1.70 | 1.76 | 2.04 | 1.97 | 1.70 |
| Up Beta | 5.74 | 4.30 | 3.53 | 3.25 | 2.06 | 1.79 |
| Down Beta | 2.55 | 2.09 | 1.79 | 1.29 | 1.63 | 1.73 |
| Up Capture | -93% | 60% | 57% | 165% | 311% | 114% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 20 | 26 | 56 | 113 | 335 |
| Down Capture | 163% | 97% | 170% | 182% | 157% | 112% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 21 | 34 | 65 | 125 | 388 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACRV | |
|---|---|---|---|---|
| ACRV | 51.7% | 95.2% | 0.86 | - |
| Sector ETF (XLV) | 26.7% | 16.0% | 1.29 | 16.8% |
| Equity (SPY) | 20.1% | 12.8% | 1.16 | 26.4% |
| Gold (GLD) | 30.9% | 29.0% | 0.92 | 11.6% |
| Commodities (DBC) | 39.9% | 20.3% | 1.54 | -7.2% |
| Real Estate (VNQ) | 9.9% | 13.7% | 0.44 | 8.4% |
| Bitcoin (BTCUSD) | -30.1% | 43.7% | -0.70 | 21.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACRV | |
|---|---|---|---|---|
| ACRV | -33.8% | 102.4% | -0.06 | - |
| Sector ETF (XLV) | 6.3% | 15.1% | 0.23 | 17.4% |
| Equity (SPY) | 13.1% | 17.2% | 0.59 | 23.0% |
| Gold (GLD) | 19.7% | 18.7% | 0.85 | 8.3% |
| Commodities (DBC) | 11.5% | 19.6% | 0.46 | 2.0% |
| Real Estate (VNQ) | 2.0% | 18.9% | 0.00 | 15.9% |
| Bitcoin (BTCUSD) | 9.6% | 52.7% | 0.37 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACRV | |
|---|---|---|---|---|
| ACRV | -18.6% | 102.4% | -0.06 | - |
| Sector ETF (XLV) | 10.5% | 16.7% | 0.51 | 17.4% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 23.0% |
| Gold (GLD) | 12.2% | 16.3% | 0.61 | 8.3% |
| Commodities (DBC) | 7.3% | 18.0% | 0.33 | 2.0% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 15.9% |
| Bitcoin (BTCUSD) | 63.4% | 66.1% | 1.03 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 8/21/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/12/2026 | 7.6% | 39.0% | |
| 5/13/2026 | 0.0% | -8.3% | -22.9% |
| 3/19/2026 | 3.7% | -7.3% | 8.5% |
| 1/8/2026 | -34.6% | -38.0% | -43.4% |
| 11/13/2025 | 8.2% | 9.2% | 16.9% |
| 8/13/2025 | 6.1% | -0.8% | 16.0% |
| 5/14/2025 | -3.5% | 0.9% | 5.3% |
| 3/25/2025 | -51.6% | -68.8% | -63.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 7 | 6 |
| # Negative | 7 | 9 | 9 |
| Median Positive | 6.8% | 9.2% | 16.5% |
| Median Negative | -5.5% | -8.3% | -16.3% |
| Max Positive | 10.6% | 39.0% | 30.9% |
| Max Negative | -51.6% | -68.8% | -63.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/12/2026 | 7.6% | 39.0% | |
| 5/13/2026 | 0.0% | -8.3% | -22.9% |
| 3/19/2026 | 3.7% | -7.3% | 8.5% |
| 1/8/2026 | -34.6% | -38.0% | -43.4% |
| 11/13/2025 | 8.2% | 9.2% | 16.9% |
| 8/13/2025 | 6.1% | -0.8% | 16.0% |
| 5/14/2025 | -3.5% | 0.9% | 5.3% |
| 3/25/2025 | -51.6% | -68.8% | -63.1% |
| 11/13/2024 | -5.5% | -24.0% | -16.3% |
| 8/13/2024 | -4.5% | 9.7% | 25.2% |
| 5/14/2024 | -1.4% | 0.8% | -11.0% |
| 3/28/2024 | 10.6% | 3.5% | 30.9% |
| 11/9/2023 | -19.2% | -8.6% | -11.4% |
| 8/11/2023 | 6.8% | -4.8% | -0.1% |
| 5/9/2023 | 6.8% | 10.9% | -1.9% |
| 3/13/2023 | 5.1% | -0.2% | -50.4% |
| SUMMARY STATS | |||
| # Positive | 9 | 7 | 6 |
| # Negative | 7 | 9 | 9 |
| Median Positive | 6.8% | 9.2% | 16.5% |
| Median Negative | -5.5% | -8.3% | -16.3% |
| Max Positive | 10.6% | 39.0% | 30.9% |
| Max Negative | -51.6% | -68.8% | -63.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/28/2023 | 10-K |
| 09/30/2022 | 12/15/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/28/2023 | 10-K |
| 09/30/2022 | 12/15/2022 | 10-Q |
| 06/30/2022 | 11/16/2022 | 424B4 |
Recent Forward Guidance
Updated 8/13/2026Latest: Q2 2026 Earnings Reported 8/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 4 | 33.3% | Raised | Guidance: 3 for 2027 | |||
Prior: Q1 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2027 Cash Runway | 3 | Raised | Guidance: 2 for Q2 2027 | ||||
Insider Activity
Updated 8/27/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blume-Jensen, Peter | President and CEO | Direct | Sell | 8272026 | 2.21 | 14,036 | 30,969 | 4,920,387 | Form |
| 2 | Peterson, Katharine | Chief Accounting Officer | Direct | Sell | 8202026 | 2.01 | 101 | 203 | 36,246 | Form |
| 3 | Miller, Mary | Chief Legal Officer | Direct | Sell | 8202026 | 2.01 | 185 | 372 | 164,838 | Form |
| 4 | Gamelin, Erick | Chief Development Officer | Direct | Sell | 8202026 | 2.01 | 400 | 804 | 105,710 | Form |
| 5 | Devroe, Eric | Chief Operating Officer | Direct | Sell | 8202026 | 2.01 | 604 | 1,214 | 294,161 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blume-Jensen, Peter | President and CEO | Direct | Sell | 8272026 | 2.21 | 14,036 | 30,969 | 4,920,387 | Form |
| 2 | Peterson, Katharine | Chief Accounting Officer | Direct | Sell | 8202026 | 2.01 | 101 | 203 | 36,246 | Form |
| 3 | Miller, Mary | Chief Legal Officer | Direct | Sell | 8202026 | 2.01 | 185 | 372 | 164,838 | Form |
| 4 | Gamelin, Erick | Chief Development Officer | Direct | Sell | 8202026 | 2.01 | 400 | 804 | 105,710 | Form |
| 5 | Devroe, Eric | Chief Operating Officer | Direct | Sell | 8202026 | 2.01 | 604 | 1,214 | 294,161 | Form |
| 6 | Blume-Jensen, Peter | President and CEO | Direct | Sell | 8202026 | 2.01 | 1,229 | 2,470 | 4,510,617 | Form |
| 7 | Blume-Jensen, Peter | President and CEO | See Footnote | Sell | 8202026 | 2.01 | 484 | 973 | 775,577 | Form |
| 8 | Levy, Adam D | Chief Financial Officer | Direct | Sell | 8062026 | 1.57 | 1,142 | 1,793 | 103,633 | Form |
| 9 | Miller, Mary | Chief Legal Officer | Direct | Sell | 7232026 | 1.76 | 573 | 1,008 | 144,661 | Form |
| 10 | Blume-Jensen, Peter | President and CEO | Direct | Buy | 1162026 | 1.68 | 49,000 | 82,124 | 3,512,512 | Form |
| 11 | Levy, Adam D | Chief Financial Officer | Direct | Buy | 1162026 | 1.70 | 8,832 | 14,999 | 35,635 | Form |
| 12 | Devroe, Eric | Chief Operating Officer | Direct | Buy | 1152026 | 1.72 | 10,000 | 17,218 | 129,665 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/30/2026